TY - JOUR
T1 - Pulmonary function and Quality of Life in a prospective cohort of (non-) hospitalized COVID-19 pneumonia survivors up to six months
AU - de Roos, Marlise P.
AU - Siegerink, Sebastiaan
AU - Dijkstra, Nynke G.
AU - Broekman, Birit Fp
AU - Brinkman, Kees
AU - Jonkman, Nini H.
AU - Bresser, Paul
N1 - Publisher Copyright: © The Author(s) 2022.
PY - 2022/7
Y1 - 2022/7
N2 - Objectives: A decrease of both diffusion capacity (DLCO) and Quality of Life (QoL) was reported after discharge in hospitalized COVID-19 pneumonia survivors. We studied three and 6 month outcomes in hospitalized and non-hospitalized patients. Methods: COVID-19 pneumonia survivors (n = 317) were categorized into non-hospitalized “moderate” cases (n = 59), hospitalized “severe” cases (n = 180) and ICU-admitted “critical” cases (n = 39). We studied DLCO and QoL (Short Form SF-36 health survey) 3 and 6 months after discharge. Data were analyzed using (repeated measures) ANOVA, Kruskal-Wallis or Chi-square test (p <.05). Results: At 3 months DLCO was decreased in 44% of moderate-, 56% of severe- and 82% of critical cases (p <.003). Mean DLCO in critical cases (64±14%) was lower compared to severe (76 ± 17%) and moderate (81±15%) cases (p <.001). A total of 159/278 patients had a decreased DLCO (<80%), of whom the DLCO improved after 6 months in 45% (71/159). However the DLCO did not normalize in the majority (89%) of the cases (63 ± 10% vs 68±10%; p <.001). At 3 months, compared to critical cases, moderate cases scored lower on SF-36 domain “general health” (p <.05); both moderate and severe cases scored lower on the domain of “health change” (p <.05). At 6 months, there were no differences in SF-36 between the subgroups. Compared to 3 months, in all groups “physical functioning” improved; in contrast all groups scored significantly lower on “non-physical” SF-36 domains. Conclusion: Three months after COVID-19 pneumonia, DLCO was still decreased in the more severely affected patients, with an incomplete recovery after 6 months. At 3 months QoL was impaired. At 6 months, while “physical functioning” improved, a decrease in “non-physical” QoL was observed but did not differ between the moderate and severely affected patients.
AB - Objectives: A decrease of both diffusion capacity (DLCO) and Quality of Life (QoL) was reported after discharge in hospitalized COVID-19 pneumonia survivors. We studied three and 6 month outcomes in hospitalized and non-hospitalized patients. Methods: COVID-19 pneumonia survivors (n = 317) were categorized into non-hospitalized “moderate” cases (n = 59), hospitalized “severe” cases (n = 180) and ICU-admitted “critical” cases (n = 39). We studied DLCO and QoL (Short Form SF-36 health survey) 3 and 6 months after discharge. Data were analyzed using (repeated measures) ANOVA, Kruskal-Wallis or Chi-square test (p <.05). Results: At 3 months DLCO was decreased in 44% of moderate-, 56% of severe- and 82% of critical cases (p <.003). Mean DLCO in critical cases (64±14%) was lower compared to severe (76 ± 17%) and moderate (81±15%) cases (p <.001). A total of 159/278 patients had a decreased DLCO (<80%), of whom the DLCO improved after 6 months in 45% (71/159). However the DLCO did not normalize in the majority (89%) of the cases (63 ± 10% vs 68±10%; p <.001). At 3 months, compared to critical cases, moderate cases scored lower on SF-36 domain “general health” (p <.05); both moderate and severe cases scored lower on the domain of “health change” (p <.05). At 6 months, there were no differences in SF-36 between the subgroups. Compared to 3 months, in all groups “physical functioning” improved; in contrast all groups scored significantly lower on “non-physical” SF-36 domains. Conclusion: Three months after COVID-19 pneumonia, DLCO was still decreased in the more severely affected patients, with an incomplete recovery after 6 months. At 3 months QoL was impaired. At 6 months, while “physical functioning” improved, a decrease in “non-physical” QoL was observed but did not differ between the moderate and severely affected patients.
KW - COVID-19 pneumonia
KW - diffusion capacity
KW - long COVID
KW - post-COVID syndrome
KW - post-acute SARS-CoV-2-syndrome
KW - pulmonary function
KW - quality of life
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85141602355&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36367295
UR - http://www.scopus.com/inward/record.url?scp=85141602355&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/14799731221114271
DO - https://doi.org/10.1177/14799731221114271
M3 - Article
C2 - 36367295
SN - 1479-9723
VL - 19
JO - Chronic Respiratory Disease
JF - Chronic Respiratory Disease
ER -